vTv Therapeutics Inc (NASDAQ:VTVT)

1.47
Delayed Data
As of Oct 15
 -0.03 / -2.04%
Today’s Change
1.41
Today|||52-Week Range
4.75
-20.97%
Year-to-Date
Ultragenyx (RARE) Begins Angelman Syndrome Study in Canada
Oct 08 / Zacks.com - Paid Partner Content